Modern COVID-19 Vaccine: Indication & Safety Information

- **Authorized use in the United States:**
  - The Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

- **Important Safety Information:**
  - Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis), to any component of the vaccine or to mRNA vaccines.
  - Appropriate medical personnel to manage immediate allergic reactions must be immediately available in the event of an anaphylactic reaction.
  - There have been rare reports of a syndrome of inflammatory cytokine release following administration of the Moderna COVID-19 Vaccine. Symptoms may include fever, headache, malaise, myalgia, arthralgia, abdominal pain, vomiting, diarrhea, dyspnea, hypotension, and hypoxia. Symptoms may begin within 4 days of vaccination. In most cases, symptoms resolve spontaneously within 48 hours. Patients should be observed for at least 15 minutes after vaccination and instructed to self-monitor and seek medical attention if such symptoms occur.
  - Avoid Moderna COVID-19 Vaccine to individuals with a known history of severe acute respiratory syndrome coronavirus 2 infection.
  - There are no data available on the interchangeability of the Moderna COVID-19 Vaccine with other vaccines.
  - Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.

- **Additional Information:**
  - The Moderna COVID-19 Vaccine is a messenger RNA (mRNA) vaccine, which means it provides instructions to the body to make a protein (the spike protein of SARS-CoV-2), which then triggers an immune response against the virus, but the vaccine itself does not contain the virus and therefore cannot cause COVID-19.
  - The vaccine is produced in cell cultures at a single site and is not processed with animal products.

mRNA-1273 Full Development Program Supports the 100-μg Dose

- **Study 101 (Phase 1) (N=120)**
  - Safety and Immunogenicity, and Dose Selection
    - Inform 100μg dose for Phase 2 and 3

- **Study 201 (Phase 2) (N=600)**
  - Safety and Immunogenicity
    - Safety Monitoring Committee safety report

- **Study 301 (Phase 3) (N=30,420)**
  - Efficacy, Safety, Immunogenicity

Forward-looking statements and disclaimer

The forward-looking statements in this presentation that are not based on historical or current data, expectations and assumptions about future events, developments or performance are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof. These forward-looking statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.

- **Moderna’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, clinical trial endpoints, and the expected timeline for regulatory approvals, may be delayed, terminated, or may never advance to the next stage of development for a variety of reasons, including the emergence of new data, safety events, changes in clinical trial endpoints, unexpected results in preclinical or clinical trials, competition, and delays associated with obtaining regulatory approval and reimbursement, and these risks and uncertainties could cause actual results to differ materially from those expressed or implied by these forward-looking statements.

- **Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements contain these words. The forward-looking statements and disclaimer in this presentation are neither promises nor guarantees, and are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained herein or to incorporate any such forward-looking statements into any subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov.

These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof. These forward-looking statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained herein or to incorporate any such forward-looking statements into any subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov.
Moderna Committed to Collecting Additional Data in a Broader Range of Patients

- Pediatric studies ongoing
- National Cancer Institute collaboration
- Post-authorization active surveillance and safety study
- Global pregnancy registry under development
- Post-authorization effectiveness study under development
- Safety and immunogenicity in solid organ transplant patients

Moderna will continue to collaborate with NIH, FDA, CDC and other agencies.

Thank you to our collaborators, investigators and subjects

- Division of Microbiology and Infectious Diseases, NIAID
- Vaccine Research Center (VRC), NIAID
- Coalition for Epidemic Preparedness Innovations
- Principal Investigators, Drs. Lisa Jackson (Kaiser Permanente Washington), Evan Anderson (Emory University School of Medicine), Nadine Rouphael (Emory University School of Medicine), Alicia Widge (VRC)
- The Emergent Company
- David R. Lamb, Vanderbilt University
- Barion L. Lewis, University of North Carolina
- Elham S. El-Sayed, Emory University
- Vaccine Immunology Program, NIAID
- Study sites, investigators and subjects

- BARDA
- Study sites, investigators, and subjects

- BARDA
- Operation Warp Speed
- NIAID and the COVID-19 Prevention Network
- Members of Diversity and Inclusion Panel
- Principal Investigators, Drs. Brandon Essink (Meridian Clinical Research), Lindsey Baden (Brigham and Women's Hospital), Hana El Sahly (Baylor College of Medicine)
- Study sites, investigators, and subjects